Triamcinolone Acetonide Patent Expiration
Triamcinolone Acetonide was first introduced by Extrovis Ag
Triamcinolone Acetonide Patents
Given below is the list of patents protecting Triamcinolone Acetonide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xipere | US9937075 | Apparatus and methods for ocular injection | May 02, 2034 | Bausch And Lomb Inc |
| Xipere | US9636332 | Methods and devices for the treatment of ocular diseases in human subjects | Nov 08, 2033 | Bausch And Lomb Inc |
| Zilretta | US8828440 | Corticosteroids for the treatment of joint pain | Aug 04, 2031 | Pacira Pharms Inc |
| Zilretta | US9555048 | Corticosteroids for the treatment of joint pain | Aug 04, 2031 | Pacira Pharms Inc |
| Triesence | US8128960 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | Dec 17, 2029 | Harrow Eye |
| Triesence | US8211880 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | Mar 10, 2029 | Harrow Eye |
| Xipere | US8636713 | Methods and devices for drug delivery to ocular tissue using microneedle | May 02, 2027 | Bausch And Lomb Inc |
| Triesence | US6395294 | Method of visualization of the vitreous during vitrectomy |
Jan 13, 2020
(Expired) | Harrow Eye |
| Nasacort Allergy 24 Hour | US5976573 | Aqueous-based pharmaceutical composition |
Jul 03, 2016
(Expired) | Chattem Sanofi |
| Nasacort Allergy 24 Hour | US6143329 | Aqueous-based pharmaceutical composition |
Jul 03, 2016
(Expired) | Chattem Sanofi |
| Nasacort Allergy 24 Hour | US7977045 | Aqueous-based pharmaceutical composition |
Jul 03, 2016
(Expired) | Chattem Sanofi |
| Nasacort Aq | US5976573 | Aqueous-based pharmaceutical composition |
Jul 03, 2016
(Expired) | Sanofi Aventis Us |
| Nasacort Aq | US6143329 | Aqueous-based pharmaceutical composition |
Jul 03, 2016
(Expired) | Sanofi Aventis Us |
| Nasacort Aq | US7977045 | Aqueous-based pharmaceutical composition |
Jul 03, 2016
(Expired) | Sanofi Aventis Us |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Triamcinolone Acetonide's patents.
Latest Legal Activities on Triamcinolone Acetonide's Patents
Given below is the list recent legal activities going on the following patents of Triamcinolone Acetonide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 16 Oct, 2023 | US8211880 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 16 Oct, 2023 | US8211880 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 15 Mar, 2023 | US8128960 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 15 Mar, 2023 | US8128960 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 07 Mar, 2023 | US8128960 |
| Email Notification Critical
| 07 Mar, 2023 | US8128960 |
| Email Notification Critical
| 07 Mar, 2023 | US8211880 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 07 Mar, 2023 | US8211880 |
| Correspondence Address Change Critical
| 01 Mar, 2023 | US8211880 |
| Correspondence Address Change Critical
| 01 Mar, 2023 | US8128960 |
Triamcinolone Acetonide's Family Patents
